Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Artiva Biotherapeutics, Inc.
A clinical-stage biotechnology company in San Diego making off-the-shelf natural killer (NK) cell therapies, its lead candidate AlloNK designed to help antibodies destroy B-cells that drive autoimmune diseases like rheumatoid arthritis and lupus. Founded in 2019 as a spin-out of South Korea's GC Cell, it can produce thousands of doses from a single umbilical cord blood donor—a ready-made therapy that doesn't wait for a patient's own cells.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements